A guide for pain management in low and middle income communities. Managing the risk of opioid abuse in patients with cancer pain

Joseph V. Pergolizzi, Gianpietro Zampogna, Robert Taylor, Edmundo Gonima, Jose Posada, Robert B. Raffa

Research output: Contribution to journalReview article

Abstract

Most patients who present with cancer have advanced disease and often suffer moderate to severe pain. Opioid therapy can be safe and effective for use in cancer patients with pain, but there are rightful concerns about inappropriate opioid use even in the cancer population. Since cancer patients live longer than ever before in history (and survivors may have long exposure times to opioid therapy), opioid misuse among cancer patients is an important topic worthy of deeper investigation. Cancer patients with pain must be evaluated for risk factors for potential opioid misuse and aberrant drug-taking behaviors assessed. A variety of validated screening tools should be used. Of particular importance is the fact that pain in cancer patients changes frequently, whether it is related to their underlying disease (progression or remission), pain related to treatment (such as painful chemotherapy-induced peripheral neuropathy), and concomitant pain unrelated to cancer (such as osteoarthritis, headache, or back pain). Fortunately, clinicians can use universal precautions to help reduce the risk of opioid misuse while still assuring that cancer patients get the pain therapy they need. Another important new "tool" in this regard is the emergence of abuse-deterrent opioid formulations.

Original languageEnglish (US)
Article number42
JournalFrontiers in Pharmacology
Volume7
Issue numberMAR
DOIs
StatePublished - Mar 1 2016

Fingerprint

Pain Management
Opioid Analgesics
Pain
Neoplasms
Universal Precautions
Cancer Pain
Peripheral Nervous System Diseases
Therapeutics
Back Pain
Osteoarthritis
Headache
Survivors
Disease Progression
History
Drug Therapy
Pharmaceutical Preparations
Population

Keywords

  • Assessment of cancer pain
  • Cancer pain
  • Malignant pain
  • Opioid analgesia
  • Opioids
  • Undertreatment of cancer pain

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

A guide for pain management in low and middle income communities. Managing the risk of opioid abuse in patients with cancer pain. / Pergolizzi, Joseph V.; Zampogna, Gianpietro; Taylor, Robert; Gonima, Edmundo; Posada, Jose; Raffa, Robert B.

In: Frontiers in Pharmacology, Vol. 7, No. MAR, 42, 01.03.2016.

Research output: Contribution to journalReview article

Pergolizzi, Joseph V. ; Zampogna, Gianpietro ; Taylor, Robert ; Gonima, Edmundo ; Posada, Jose ; Raffa, Robert B. / A guide for pain management in low and middle income communities. Managing the risk of opioid abuse in patients with cancer pain. In: Frontiers in Pharmacology. 2016 ; Vol. 7, No. MAR.
@article{f5001d4597b048f6afb30362408e6224,
title = "A guide for pain management in low and middle income communities. Managing the risk of opioid abuse in patients with cancer pain",
abstract = "Most patients who present with cancer have advanced disease and often suffer moderate to severe pain. Opioid therapy can be safe and effective for use in cancer patients with pain, but there are rightful concerns about inappropriate opioid use even in the cancer population. Since cancer patients live longer than ever before in history (and survivors may have long exposure times to opioid therapy), opioid misuse among cancer patients is an important topic worthy of deeper investigation. Cancer patients with pain must be evaluated for risk factors for potential opioid misuse and aberrant drug-taking behaviors assessed. A variety of validated screening tools should be used. Of particular importance is the fact that pain in cancer patients changes frequently, whether it is related to their underlying disease (progression or remission), pain related to treatment (such as painful chemotherapy-induced peripheral neuropathy), and concomitant pain unrelated to cancer (such as osteoarthritis, headache, or back pain). Fortunately, clinicians can use universal precautions to help reduce the risk of opioid misuse while still assuring that cancer patients get the pain therapy they need. Another important new {"}tool{"} in this regard is the emergence of abuse-deterrent opioid formulations.",
keywords = "Assessment of cancer pain, Cancer pain, Malignant pain, Opioid analgesia, Opioids, Undertreatment of cancer pain",
author = "Pergolizzi, {Joseph V.} and Gianpietro Zampogna and Robert Taylor and Edmundo Gonima and Jose Posada and Raffa, {Robert B.}",
year = "2016",
month = "3",
day = "1",
doi = "10.3389/fphar.2016.00042",
language = "English (US)",
volume = "7",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - A guide for pain management in low and middle income communities. Managing the risk of opioid abuse in patients with cancer pain

AU - Pergolizzi, Joseph V.

AU - Zampogna, Gianpietro

AU - Taylor, Robert

AU - Gonima, Edmundo

AU - Posada, Jose

AU - Raffa, Robert B.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Most patients who present with cancer have advanced disease and often suffer moderate to severe pain. Opioid therapy can be safe and effective for use in cancer patients with pain, but there are rightful concerns about inappropriate opioid use even in the cancer population. Since cancer patients live longer than ever before in history (and survivors may have long exposure times to opioid therapy), opioid misuse among cancer patients is an important topic worthy of deeper investigation. Cancer patients with pain must be evaluated for risk factors for potential opioid misuse and aberrant drug-taking behaviors assessed. A variety of validated screening tools should be used. Of particular importance is the fact that pain in cancer patients changes frequently, whether it is related to their underlying disease (progression or remission), pain related to treatment (such as painful chemotherapy-induced peripheral neuropathy), and concomitant pain unrelated to cancer (such as osteoarthritis, headache, or back pain). Fortunately, clinicians can use universal precautions to help reduce the risk of opioid misuse while still assuring that cancer patients get the pain therapy they need. Another important new "tool" in this regard is the emergence of abuse-deterrent opioid formulations.

AB - Most patients who present with cancer have advanced disease and often suffer moderate to severe pain. Opioid therapy can be safe and effective for use in cancer patients with pain, but there are rightful concerns about inappropriate opioid use even in the cancer population. Since cancer patients live longer than ever before in history (and survivors may have long exposure times to opioid therapy), opioid misuse among cancer patients is an important topic worthy of deeper investigation. Cancer patients with pain must be evaluated for risk factors for potential opioid misuse and aberrant drug-taking behaviors assessed. A variety of validated screening tools should be used. Of particular importance is the fact that pain in cancer patients changes frequently, whether it is related to their underlying disease (progression or remission), pain related to treatment (such as painful chemotherapy-induced peripheral neuropathy), and concomitant pain unrelated to cancer (such as osteoarthritis, headache, or back pain). Fortunately, clinicians can use universal precautions to help reduce the risk of opioid misuse while still assuring that cancer patients get the pain therapy they need. Another important new "tool" in this regard is the emergence of abuse-deterrent opioid formulations.

KW - Assessment of cancer pain

KW - Cancer pain

KW - Malignant pain

KW - Opioid analgesia

KW - Opioids

KW - Undertreatment of cancer pain

UR - http://www.scopus.com/inward/record.url?scp=84973099664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973099664&partnerID=8YFLogxK

U2 - 10.3389/fphar.2016.00042

DO - 10.3389/fphar.2016.00042

M3 - Review article

C2 - 26973529

AN - SCOPUS:84973099664

VL - 7

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAR

M1 - 42

ER -